News Search Results
Mar 10, 2025, 13:00 ET Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in the North American Market
Annual Meeting, which was held in Orlando, Florida, from March 7 to 9. The American Academy of Dermatology is the largest, most influential, and most representative dermatologic association. During the event, attendees had the opportunity to
More news about: Wingderm Electro-optics Ltd.
Mar 10, 2025, 13:00 ET Wingderm® Presents at the 2025 AAD Annual Meeting, Strengthening Its Presence in the North American Market
Annual Meeting, which was held in Orlando, Florida, from March 7 to 9. The American Academy of Dermatology is the largest, most influential, and most representative dermatologic association. During the event, attendees had the opportunity to
More news about: Wingderm Electro-optics Ltd.
Mar 10, 2025, 07:30 ET Alphyn Poster at American Academy of Dermatology Annual Meeting Highlights Potential of Zabalafin Hydrogel as Singular, Comprehensive Treatment for Atopic Dermatitis
Zabalafin Hydrogel at the American Academy of Dermatology (AAD) annual meeting demonstrating the topical therapeutic's potential as a singular comprehensive approach to effectively managing the
More news about: Alphyn Biologics, Inc.
Mar 08, 2025, 13:00 ET Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
eyebrows and eyelashes at Week 36. Findings from the Phase 3 BRAVE-AA-PEDS study were presented in a late-breaker presentation at the American Academy of Dermatology (AAD) Annual Meeting taking place March 7-11 in Orlando.1
More news about: Eli Lilly and Company
Mar 08, 2025, 11:00 ET Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy of Dermatology (AAD) Meeting in Orlando, FL. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive
More news about: Q32 Bio
Mar 08, 2025, 09:00 ET Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Data from the Phase 3 ICONIC-LEADa study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting, show once daily icotrokinra demonstrated significant skin clearance and a favorable safety profile in adults and
More news about: Johnson & Johnson
Mar 08, 2025, 06:00 ET AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
vaccinations. HORIZON, top-line results of which were previously shared, will be presented as a late-breaking abstract at the 2025 American Academy of Dermatology Annual Meeting. Results from IGNITE, SHUTTLE and VOYAGER will be presented at upcoming congresses or published in peer-reviewed journals.
More news about: Amgen
Mar 08, 2025, 06:00 ET AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
vaccinations. HORIZON, top-line results of which were previously shared, will be presented as a late-breaking abstract at the 2025 American Academy of Dermatology Annual Meeting. Results from IGNITE, SHUTTLE and VOYAGER will be presented at upcoming congresses or published in peer-reviewed journals.
More news about: Kyowa Kirin
Mar 07, 2025, 09:15 ET ILUMYA® (tildrakizumab-asmn) Found Effective for Treatment of Moderate-to-Severe Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference
Data Presented at American Academy of Dermatology Shows Significant Improvement in Moderate-to-Severe Nail Psoriasis with No New Safety Signals PRINCETON, N.J.,
More news about: Sun Pharmaceutical Industries Inc., USA (Sun Pharma)
Mar 07, 2025, 09:08 ET Candela Announces Launch of the Glacē™ Treatment at American Academy of Dermatology (AAD) Annual Meeting
in Marlborough, MA, today announced the global launch of the Glacē solution (pronounced ˈGLASS-ee / 'GLASS-ie / 'GLASS-y) at the 2025 American Academy of Dermatology (AAD) Annual Meeting. Inspired by the K-beauty trend for 'glass skin' – a smooth, poreless, and radiant complexion - the Glacē treatment
More news about: CANDELA
Mar 07, 2025, 09:01 ET Head-to-Head Preclinical Studies of SFA-002 as a Novel Psoriasis Treatment Presented at the 2025 American Academy of Dermatology Annual Meeting
inflammatory and autoimmune diseases, today announced the presentation of two posters on oral psoriasis drug candidate SFA-002 at the 2025 American Academy of Dermatology Annual Meeting, to take place from March 7 – 11 in Orlando, Florida.
More news about: SFA Therapeutics, Inc.
Mar 07, 2025, 09:00 ET Ulike nimmt an der jährlichen AAD-Tagung 2025 teil, um Fortschritte in der IPL-Technologie zu präsentieren
IPL-Haarentfernung für zu Hause, hat sich mit Dr. Adam J. Rubinstein zusammengetan, um erstmals an der Jahrestagung der American Academy of Dermatology (AAD) 2025 teilzunehmen. Dr. Rubinstein, ein anerkannter Experte für Laser-Haarbehandlung, unterstützte die Wirksamkeit der Innovationen
More news about: Ulike
Mar 07, 2025, 09:00 ET Ulike Attends 2025 AAD Annual Meeting to Highlight IPL Technology Advancements
of at-home IPL hair removal technology, collaborated with Dr. Adam J. Rubinstein to appear at the 2025 American Academy of Dermatology (AAD) Annual Meeting for the first time. A renowned expert in laser hair treatment, Dr. Rubinstein supported the effectiveness of Ulike's
More news about: Ulike
Mar 07, 2025, 09:00 ET New analyses on the potential impact of SPEVIGO® in generalized pustular psoriasis patient-reported outcomes presented at AAD 2025
March 7, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim announced new analyses to be presented at the American Academy of Dermatology (AAD) annual meeting in Orlando that explore the effect that SPEVIGO® (spesolimab-sbzo) may
More news about: Boehringer Ingelheim
Mar 07, 2025, 08:30 ET Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis
moderate-to-severe atopic dermatitis (eczema) at three years. These findings from the ADjoin long-term extension study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando.1
More news about: Eli Lilly and Company
Mar 07, 2025, 08:01 ET Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek™ Biosimilar to Ustekinumab for Chronic Plaque Psoriasis
Stelara (Ustekinumab) in adult patients with moderate to severe chronic plaque psoriasis (PsO). The data are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida.
More news about: Biocon Biologics Ltd.
Mar 07, 2025, 08:00 ET Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies
dermatology study of more than 7,000 enrolled patients with two poster presentations on patients with Hidradenitis Suppurativa (HS) at the American Academy of Dermatology (AAD) annual meeting in Orlando, FL, March 7-11, 2025.
More news about: Target RWE
Mar 07, 2025, 08:00 ET BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
3 trial in psoriatic arthritis." UCB's data for BIMZELX in moderate-to-severe PSO will be presented as six posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, U.S., March 7–11.1-6 These abstracts complement other
More news about: UCB
Mar 07, 2025, 08:00 ET BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
potential to address the unmet needs of people living with HS." UCB's data in HS will be presented as seven posters at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, March 7-11.2-7,11 These
More news about: UCB
Mar 07, 2025, 07:00 ET AMERICAN ACADEMY OF DERMATOLOGY INSTALLS NEW OFFICERS, BOARD MEMBERS
/PRNewswire/ -- Four new officers and four new board members will be installed immediately upon conclusion of the 2025 Annual Meeting of the American Academy of Dermatology. The officers and board members are all board-certified dermatologists and members of the AAD, the world's largest dermatologic society
More news about: American Academy of Dermatology
Mar 07, 2025, 07:00 ET SUSAN C. TAYLOR, MD, FAAD, ASSUMES PRESIDENCY OF THE AMERICAN ACADEMY OF DERMATOLOGY
board-certified dermatologist Susan C. Taylor, MD, FAAD, will begin her one-year term as president of the American Academy of Dermatology at the close of the AAD's Annual Meeting. Dr. Taylor will lead the world's largest dermatologic society that represents nearly
More news about: American Academy of Dermatology
Mar 07, 2025, 07:00 ET TRANSFORM YOUR SKIN HEALTH: DIET AND LIFESTYLE TAKE CENTER STAGE AT 2025 AAD ANNUAL MEETING
ORLANDO, Fla., March 7, 2025 /PRNewswire/ -- The 2025 American Academy of Dermatology Annual Meeting will take place March 7-11 in Orlando. The meeting will feature
More news about: American Academy of Dermatology
Mar 06, 2025, 07:30 ET HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
presentations will occur at the United States Cutaneous Lymphoma Consortium (USCLC) Workshop (March 6, 2025) and the American Academy of Dermatology (AAD) Annual Meeting (March 7-11, 2025). Ellen Kim, MD, Director, Penn Cutaneous
More news about: SOLIGENIX, INC.
Mar 05, 2025, 13:40 ET Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025, highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The
More news about: Hoth Therapeutics, Inc.
Mar 03, 2025, 08:35 ET skinbetter science® Launches BioRewind Skin Health Dietary Supplement to Combat Skin Glycation
reverse the visible effects of glycation, a key contributor to skin agingData to be presented via two posters at the Annual American Academy of Dermatology (AAD) Meeting in Orlando, FLLOS
More news about: skinbetter science